Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 5/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22835873 | 1.00 | HSD17B13 (0.39) | HSD17B13IRAK4CRBNESR2TYK2 | |
| SCHEMBL22836722 | 0.90 | IRAK4 (0.41) | HSD17B13IRAK4CRBNTYK2KDM2B | |
| SCHEMBL22849080 | 0.90 | IRAK4 (0.41) | HSD17B13IRAK4CRBNTYK2KDM2B | |
| SCHEMBL16595488 | 0.86 | BACE1 (0.38) | HSD17B13TYK2 | |
| SCHEMBL27213907 | 0.84 | HSD17B13 (0.38) | HSD17B13IRAK4CRBNTYK2 | |
| SCHEMBL27230890 | 0.84 | HSD17B13 (0.38) | HSD17B13IRAK4CRBNTYK2 | |
| Hydrochloric Acid SCHEMBL30849268 | 0.83 | HSD17B13 (0.37) | HSD17B13IRAK4CRBNTYK2 | |
| SCHEMBL22835612 | 0.82 | HSD17B13 (0.41) | HSD17B13IRAK4CRBNTYK2KDM2B | |
| SCHEMBL22835613 | 0.82 | HSD17B13 (0.41) | HSD17B13IRAK4CRBNTYK2KDM2B | |
| SCHEMBL26351602 | 0.81 | HSD17B13 (0.41) | HSD17B13IRAK4CRBNTYK2KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | HSD17B13 2379/4885IRAK4 3/4885CRBN 39/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | HSD17B13 3799/4885IRAK4 1/4885CRBN 322/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD17B13 3277/4885IRAK4 4/4885CRBN 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.